GI-6301: Phase II started

GlobeImmune began the double-blind, U.S. Phase II GI-6301-02 trial to evaluate subcutaneous GI-6301 plus radiotherapy in about 50 patients. Patients will receive 3 doses of GI-6301 or placebo given 2 weeks apart prior to radiotherapy. Patients will then receive GI-6301 or placebo every 2 weeks for 6 doses, followed by dosing every month for 4 doses and dosing every 3 months for at least 2 years. The dosing may be adjusted to every 6-12 months after 2 years. Patients in the placebo arm may cross over to GI-6301 at disease progression. ...